Drug repositioning strategies were employed to explore new therapeutic indications for existing drugs that may exhibit dual negative mGluR1/5 modulating activities as potential treatments for neuropathic pain.
A customized in silico-in vitro-in vivo drug repositioning scheme was assembled and implemented to search available drug libraries for compounds with dual mGluR1/5 antagonistic activities, that were then evaluated using in vitro functional assays and, for validated hits, in an established animal model for neuropathic pain.
Tizoxanide, the primary active metabolite of the FDA approved drug nitazoxanide, fit in silico pharmacophore models constructed for both mGluR1 and mGluR5. Subsequent calcium (Ca++) mobilization functional assays confirmed that tizoxanide exhibited appreciable antagonist activity for both mGluR1 and mGluR5 (IC50 = 1.8 μM and 1.2 μM, respectively). The in vivo efficacy of nitazoxanide administered by intraperitoneal injection was demonstrated in a rat model for neuropathic pain.
The major aim of the present study was to demonstrate the utility of an in silico-in vitro-in vivo drug repositioning protocol to facilitate the repurposing of approved drugs for new therapeutic indications. As an example, this particular investigation successfully identified nitazoxanide and its metabolite tizoxanide as dual mGluR1/5 negative modulators. A key finding is the vital importance for drug screening libraries to include the structures of drug active metabolites, such as those emanating from prodrugs which are estimated to represent 5–7% of marketed drugs.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Comprehensive clinical drug library
Central nervous system
G-protein coupled receptor
Metabotropic glutamate receptor
Molecular Operating Environment
Virtual clinical drug library
Center for Drug Evaluation and Research and FDA Basics. Is it true FDA is approving fewer new drugs lately? www.fda.gov/AboutFDA/Transparency/Basics/ucm247348.htm.
Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013;93:335–41.
Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease. Pharmaceuticals (Basel). 2013;6:1304–21.
Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov. 2012;11:833–46.
Law GL, Tisoncik-Go J, Korth MJ, Katze MG. Drug repurposing: a better approach for infectious disease drug discovery? Curr Opin Immunol. 2013;25:588–92.
Bastosand LF, Coelho MM. Drug repositioning: playing dirty to kill pain. CNS Drugs. 2014;28:45–61.
Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2014;0. doi:10.1038/onc.2014.72
Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, et al. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther. 2013;12:1896–905.
Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J, et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother. 2013;57:2029–35.
Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3:80ps16.
Ekinsand S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res. 2011;28:1785–91.
Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091–7.
Connand PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997;37:205–37.
Ribeiro FM, Paquet M, Cregan SP, Ferguson SS. Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets. 2010;9:574–95.
Chiechioand S, Nicoletti F. Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol. 2012;12:28–34.
Osikowicz M, Mika J, Przewlocka B. The glutamatergic system as a target for neuropathic pain relief. Exp Physiol. 2013;98:372–84.
Pitsikas N. The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders? Eur J Pharmacol. 2014;723:181–4.
Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology. 2013;66:40–52.
Vaidya A, Jain S, Jain AK, Agrawal A, Kashaw SK, Jain SK, et al. Metabotropic glutamate receptors: a review on prospectives and therapeutic aspects. Mini Rev Med Chem. 2013;13:1967–81.
Pomierny-Chamiolo L, Rup K, Pomierny B, Niedzielska E, Kalivas PW, Filip M. Metabotropic glutamatergic receptors and their ligands in drug addiction. Pharmacol Ther. 2014;142:281–305.
D’Antoni S, Spatuzza M, Bonaccorso CM, Musumeci SA, Ciranna L, Nicoletti F, et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev. 2014.
Pin JP, De Colle C, Bessis AS, Acher F. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol. 1999;375:277–94.
Owen DR. Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu(1)). ACS Chem Neurosci. 2011;2:394–401.
Rocher JP, Bonnet B, Bolea C, Lutjens R, Le Poul E, Poli S, et al. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem. 2011;11:680–95.
Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60:1017–41.
Kulkarni SS, Zou MF, Cao J, Deschamps JR, Rodriguez AL, Conn PJ, et al. Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. J Med Chem. 2009;52:3563–75.
Lindsley CW, Bates BS, Menon UN, Jadhav SB, Kane AS, Jones CK, et al. (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem Neurosci. 2011;2:471–82.
Zauhar RJ, Gianti E, Welsh WJ. Fragment-based shape signatures: a new tool for virtual screening and drug discovery. J Comput Aided Mol Des. 2013;27:1009–36.
Hartman I, Gillies AR, Arora S, Andaya C, Royapet N, Welsh WJ, et al. Application of screening methods, shape signatures and engineered biosensors in early drug discovery process. Pharm Res. 2009;26:2247–58.
Chekmarev D, Kholodovych V, Kortagere S, Welsh WJ, Ekins S. Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharm Res. 2009;26:2216–24.
Kortagere S, Chekmarev D, Welsh WJ, Ekins S. Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res. 2009;26:1001–11.
Kortagere S, Chekmarev D, Welsh WJ, Ekins S. New predictive models for blood–brain barrier permeability of drug-like molecules. Pharm Res. 2008;25:1836–45.
Wang CY, Ai N, Arora S, Erenrich E, Nagarajan K, Zauhar R, et al. Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach. Chem Res Toxicol. 2006;19:1595–601.
Nagarajan K, Zauhar R, Welsh WJ. Enrichment of ligands for the serotonin receptor using the shape signatures approach. J Chem Inf Model. 2005;45:49–57.
Bragaand RC, Andrade CH. Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? Curr Top Med Chem. 2013;13:1127–38.
Zauhar RJ, Moyna G, Tian L, Li Z, Welsh WJ. Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem. 2003;46:5674–90.
Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56–63.
Readheadand B, Dudley J. Translational bioinformatics approaches to drug development. Adv Wound Care (New Rochelle). 2013;2:470–89.
Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7:255–70.
Choiand SZ, Son MW. Novel botanical drug for the treatment of diabetic neuropathy. Arch Pharm Res. 2011;34:865–7.
ACKNOWLEDGMENTS AND DISCLOSURES
The authors acknowledge the resources, encouragement and support provided by Snowdon, Inc. (Monmouth Junction, NJ, USA). WJW wishes to acknowledge partial support for this work from NIH-NIEHS P30 ES005022.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
(DOCX 53 kb)
About this article
Cite this article
Ai, N., Wood, R.D. & Welsh, W.J. Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study. Pharm Res 32, 2798–2807 (2015). https://doi.org/10.1007/s11095-015-1665-7
- group I metabotropic glutamate receptor (mGluR)
- in silico drug repositioning